Helicase-primase inhibitors

Drugs of the Future

Volumn 28, Issue 3, 2003, Pages 257-265

  Kleymann, Gerald ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BAY 57 1293; BILS 179 BS; CIPROFLOXACIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; DOXORUBICIN; EPIRUBICIN; ER622; FAMCICLOVIR; FLUDARABINE PHOSPHATE; GATIFLOXACIN; HELICASE PRIMASE INHIBITOR; IDARUBICIN; IRINOTECAN; LEVOFLOXACIN; MITOXANTRONE; MOXIFLOXACIN; NOGALAMYCIN; NORFLOXACIN; OFLOXACIN; PENCICLOVIR; T 157602; TOPOTECAN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALRUBICIN;

ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; DNA REPLICATION; DNA SUPERCOILING; DNA TRANSCRIPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; MICROBIAL GROWTH; MOLECULAR BIOLOGY; NONHUMAN; PARAMETER; PROTEIN STRUCTURE; REVIEW; RNA REPLICATION; RNA TRANSCRIPTION; SIDE EFFECT;

EID: 0013118133     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.03.856930     Document Type: Review

References (77)

1. Abdel-Monem, M., Hoffmann-Berling, H. Enzymic unwinding of DNA. 1. Purification and characterization of a DNA-dependent ATPase from Escherichia coli. Eur J Biochem 1976, 65: 431-40.
2. Abdel-Monem, M., Durwald, H., Hoffmann-Berling, H. Enzymic unwinding of DNA. 2. Chain separation by an ATP-dependent DNA unwinding enzyme. Eur J Biochem 1976, 65: 441-9.
3. Bell, S.P., Dutta, A. DNA replication in eukaryotic cells. Annu Rev Biochem 2002, 71: 333-74.
4. Benkovic, S.J., Valentine, A.M., Salinas, F. Replisomemediated DNA replication. Annu Rev Biochem 2001, 70: 181-208.
5. Caruthers, J.M., McKay, D.B. Helicase structure and mechanism. Curr Opin Struct Biol 2002, 12: 123-33.
6. Soultanas, R, Wigley, D.B. DNA helicases: "Inching forward". Curr Opin Struct Biol 2000, 10: 124-8.
7. Hall, M.C., Matson, S.W. Helicase motifs: The engine that powers DNA unwinding. Mol Microbiol 1999, 34: 867-77.
8. Gorbalenya, A.E., Koonin, E.V. Helicases: Amino acid sequence comparison and structure-function relationship. Curr Opin Struct Biol 1993, 3: 419-429.
9. Luking, A., Stahl, U., Schmidt, U. The protein family of RNA helicases. Crit Rev Biochem Mol Biol 1998, 33: 259-96.
10. Kadare, G., Haenni, A.L. Virus-encoded RNA helicases. J Virol 1997, 71: 2583-90.
11. Knipe, D.M., Howley, P.M. (Eds.). Fields Virology, 4th Ed. Lippincott Williams & Wilkins: Philadelphia 2001.
12. Frick, D.N., Richardson, C.C. DNA primases. Annu Rev Biochem 2001, 70: 39-80.
13. Wang, J.C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 2002, 3: 430-40.
14. Kato, S., Kikuchi, A. DNA topoisomerase: The key enzyme that regulates DNA super structure. Nagoya J Med Sci 1998, 61: 11-26.
15. Berger, J.M. Type II DNA topoisomerases. Curr Opin Struct Biol 1998, 8: 26-32.
16. Furuichi, Y. Premature aging and predisposition to cancers caused by mutations in RecQ family helicases. Ann NY Acad Sci 2001, 928: 121-31.
17. van Brabant, A.J., Stan, R., Ellis, N.A. DNA helicases, genomic instability, and human genetic disease. Annu Rev Genomics Hum Genet 2000, 1: 409-59.
18. Zeiler, H.J., Metzger, K.G., Schacht, P., Grohe, K. Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy. Drugs Exp Clin Res 1985, 11: 343-50.
19. Sanders, C.C. Ciprofloxacin: In vitro activity, mechanism of action, and resistance. Rev Infect Dis 1988, 10: 516-27.
20. LeBel, M. Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988, 8: 3-33.
21. Hooper, D.C. Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis 2001, 32 Suppl 1: S9-15.
22. Schmitz, F.J., Higgins, P.G., Mayer, S., Fluit, A.C., Dalhoff, A. Activity of quinolones against Gram-positive cocci: Mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 2002, 21: 647-59.
23. Bearden, D.T., Danziger, L.H. Mechanism of action of and resistance to quinolones. Pharmacotherapy 2001, 21 (10, Pt 2): 224-32S.
24. Oliphant, C.M., Green, G.M. Quinolones: A comprehensive review. Am Fam Physician 2002, 65: 455-64.
25. Schaeffer, A.J. The expanding role of fluoroquinolones. Am J Med 2002, 113 (Suppl. 1A): 45-54S.
26. Kim, O.K., Ohemeng, K., Barrett, J.F. Advances in DNA gyrase inhibitors. Expert Opin Investig Drugs 2001, 10: 199-212.
27. Spector, F.C., Liang, L., Giordano, H., Sivaraja, M., Peterson, M.G. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5UL8-UL52 complex. J Virol 1998, 72: 6979-87.
28. Crute, J.J., Grygon, C.A., Hargrave, K.D. et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002, 8: 386-91.
29. Kleymann, G., Fischer, R., Betz, U.A. et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002, 8: 392-8.
30. Crumpacker, C.S., Schaffer, P.A. New anti-HSV therapeutics target the helicase-primase complex. Nat Med 2002, 8: 327-8.
31. Betz, U.A., Fischer, R., Kleymann, G., Hendrix, M., Rubsamen-Waigmann, H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother 2002, 46: 1766-72.
32. Crute, J.J., Faucher, A.M., Gyrgon, C.A. et al. (Boehringer Ingelheim). Phenyl thiazole derivatives with anti-herpes virus properties. WO 9724343.
33. Flygare, J.A., Jaen, J.J.C., Kearney, P.C., Medina, J.C., Sivaraja, M. (Tularik Inc.). Antiviral agents. WO 9942455.
34. a). Fischer, R., Kleymann, G., Betz, U. et al. (Bayer AG). Thiazolyl amide derivatives. WO 0147904.
35. b) Fischer, R., Kleymann, G., Bumeister, J. et al. (Bayer AG). Thiazolyl urea derivatives and their utilization as antiviral agents. WO 0053591.
36. Matthews, J.T., Terry, B.J., Field, A.K. The structure and function of the HSV DNA replication proteins: Defining novel antiviral targets. Antiviral Res 1993, 20: 89-114.
37. Lehman, I.R., Boehmer, P.E. Replication of herpes simplex virus DNA. J Biol Chem 1999, 274: 28059-62.
38. Falkenberg, M., Elias, P., Lehman, I.R. The herpes simplex virus type 1 helicase-primase. Analysis of helicase activity. J Biol Chem 1998, 273: 32154-7.
39. Crute, J.J., Lehman, I.R. Herpes simplex virus-1 helicase-primase. Physical and catalytic properties. J Biol Chem 1991, 266: 4484-8.
40. Crute, J.J., Tsurumi, T., Zhu, L.A. et al. Herpes simplex virus 1 helicase-primase: A complex of three herpes-encoded gene products. Proc Natl Acad Sci USA 1989, 86: 2186-9.
41. Graves-Woodward, K.L., Gottlieb, J., Challberg, M.D., Weller, S.K. Biochemical analyses of mutations in the HSV-1 helicase-primase that alter ATP hydrolysis, DNA unwinding, and coupling between hydrolysis and unwinding. J Biol Chem 1997, 272: 4623-30.
42. Kwong, A.D., Kim, J.L., Lin, C. Structure and function of hepatitis C virus NS3 helicase. Curr Top Microbiol Immunol 2000, 242: 171-96.
43. Wilson, V.G., West, M., Woytek, K., Rangasamy, D. Papillomavirus E1 proteins: Form, function, and features. Virus Genes 2002, 24: 275-90.
44. Borowski, P., Schalinski, S., Schmitz, H. Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res 2002, 55: 397.
45. Ideo, G., Bellobuono, A. New therapies for the treatment of chronic hepatitis C. Curr Pharm Des 2002, 8: 959-66.
46. Zein, N.N. Experimental and emerging therapies for chronic hepatitis C virus infection. Expert Opin Investig Drugs 2001, 10: 1457-69.
47. Hicham Alaoui-Ismaili, M., Gervais, C., Brunette, S. et al. A novel high throughput screening assay for HCV NS3 helicase activity. Antiviral Res 2000, 46: 181-93.
48. Francke, B., Margolin, J. Effect of novobiocin and other DNA gyrase inhibitors on virus replication and DNA synthesis in herpes simplex virus type 1-infected BHK cells. J Gen Virol 1981, 52: 401-4.
49. Ikeda, S., Yazawa, M., Nishimura, C. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res 1987, 8: 103-13.
50. Wentland, M.P., Perni, R.B., Dorff, P.H. et al. Antiviral properties of 3-quinolinecarboxamides: A series of novel non-nucleoside antiherpetic agents. Drug Des Discov 1997, 15: 25-38.
51. Wentland, M.P., Carlson, J.A., Dorff, P.H. et al. Cyclic variations of 3-quinolinecarboxamides and effects on antiherpetic activity. J Med Chem 1995, 38: 2541-5.
52. Wentland, M.P., Perni, R.B., Dorff, P.H. et al. 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. J Med Chem 1993, 36: 1580-96.
53. Akanitapichat, P., Lowden, C.T., Bastow, K.F. 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res 2000, 45: 123-34.
54. Ebert, S.N., Shtrom, S.S., Muller, M.T. Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent. J Virol 1990, 64: 4059-66.
55. Yamada, Y., Yamamoto, N., Maeno, K., Nishiyama, Y. Role of DNA topoisomerase I in the replication of herpes simplex virus type 2. Arch Virol 1990, 110: 121-7.
56. Pessina, A., Mineo, E., Gribaldo, L., Neri, M.G. Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2. Arch Virol 1992, 122: 263-9.
57. Nozawa, N., Daikoku, T., Yamauchi, Y., Takakuwa, H., Goshima, F., Yoshikawa, T., Nishiyama, Y. Identification and characterization of the UL 7 gene product of herpes simplex virus type 2. Virus Genes 2002, 24: 257-66.
58. Staker, B.L., Hjerrild, K., Feese, M.D., Behnke, C.A., Burgin, A.B. Jr., Stewart, L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002, 99: 15387-92.
59. Earnshaw, D.L., Moore, K.J., Greenwood, C.J. et al. Timeresolved fluorescence energy transfer DNA helicase assays for high throughput screening. J Biomol Screen 1999, 4: 239-248.
60. Sivaraja, M., Giordano, H., Peterson, M.G. High-throughput screening assay for helicase enzymes. Anal Biochem 1998, 265: 22-7.
61. Kleymann, G. Novel agents and strategies to treat herpes simplex infections. Expert Opin Investig Drugs 2003, 12: 165-83.
62. O'Brien, J.J., Campoli-Richards, D.M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989, 37: 233-309.
63. Whitley, R.J., Gnann, J.W. Jr. Acyclovir: A decade later. N Engl J Med 1992, 327: 782-9. Erratum in: N Engl J Med 1993, 328: 671 and N Engl J Med 1997, 337: 1703.
64. Whitley, R.J., Gnann, J.W. Jr. Acyclovir: A decade later. N Engl J Med 1992, 327: 782-9. Erratum in: N Engl J Med 1993, 328: 671 and N Engl J Med 1997, 337: 1703.
65. Whitley, R.J., Gnann, J.W. Jr. Acyclovir: A decade later. N Engl J Med 1992, 327: 782-9. Erratum in: N Engl J Med 1993, 328: 671 and N Engl J Med 1997, 337: 1703.
66. Perry, C.M., Faulds, D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996, 52: 754-72.
67. Beutner, K.R. Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995, 28: 281-90.
68. Bell, A.R. Valaciclovir update. Adv Exp Med Biol 1999, 458: 149-57.
69. Jarvest, R.L., Sutton, D., Vere Hodge, R.A. Famciclovir. Discovery and development of a novel antiherpesvirus agent. Pharm Biotechnol 1998, 11: 313-43.
70. Dicker, I.B., Blasecki, J.W., Seetharam, S. Herpes simplex type 1:lacZ recombinant viruses. II. Microtiter plate-based colorimetric assays for the discovery of new antiherpes agents and the points at which such agents disrupt the viral replication cycle. Antiviral Res 1995, 28: 213-24.
71. Crute, J.J., Lehman, I.R., Gambino, J. et al. Inhibition of herpes simplex virus type 1 helicase-primase by (dichloroanilino)purines and -pyrimidines. J Med Chem 1995, 38: 1820-5.
72. Medveczky, M., Yang, T.F., Gambino, J., Medveczky, P., Wright, G.E. Haloanilino derivatives of pyrimidines, purines, and purine nucleoside analogs: Synthesis and activity against human cytomegalovirus. J Med Chem 1995, 38: 1811-9.
73. Tatsu, N. et al. (Yoshitomi Pharma). (Yoshitomi Pharma). Aminothiazoles are useful as pharmaceuticals having pharmacological activity such as e.g. antiinflammatory, immunoregulating, antiphlogistic-analgesics, antiulcer and psychotropic action. JP 63060978A.
74. Collins, P., Darby G. Laboratory studies of herpes simplex virus strains resistant to acyclovir. Med Virol 1991, 1: 19-8.
75. Coen, D.M. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 1994, 2: 481-5.
76. Bertino, J. Jr, Fish, D. The safety profile of the fluoroquinolones. Clin Ther 2000, 22: 798-817.
77. Field, H-J. Famciclovir-origins, progress and prospects. Exp Opin Invest Drugs 1996, 5: 925-38.